FOLD

MKT CAP:$5B

Amicus Therapeutics, Inc.

Market Cap

$5B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$14.46+$0.19 (+1.33%)

Apr 23, 2026

Company Details

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment...

CEO

Bradley L. Campbell

IPO Date

May 31, 2007

Website

amicusrx.com

Key Metrics TTM

Revenue

$634M

+20.0% YoY

Net Income

-$27M

EPS (Diluted)

-$0.09

Free Cash Flow

$30M

Revenue / Share

$2.02

Gross Margin

87.9%

Operating Margin

5.2%

Net Margin

-4.3%

FCF Margin

4.7%

P/S

7.2x

P/E

—

Earnings Reports

Q1 2026

May 7, 2026

PENDING

FY 2025

Feb 20, 2026

$634M+20.0%EPS -$0.09

Q4 2025

Feb 20, 2026

$185M+23.7%EPS $0.01

Q3 2025

Nov 4, 2025

$169M+19.5%EPS $0.06

Q2 2025

Jul 31, 2025

$155M+22.1%EPS -$0.08

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$79M	$71M	-$75M
Q2 22	$81M	$73M	-$61M
Q3 22	$82M	$68M	-$34M
Q4 22	$88M	$79M	-$42M
Q1 23	$86M	$79M	-$38M
Q2 23	$95M	$85M	-$19M
Q3 23	$104M	$94M	-$17M
Q4 23	$115M	$104M	-$4M
Q1 24	$110M	$97M	-$28M
Q2 24	$127M	$115M	$15M
Q3 24	$142M	$128M	$22M
Q4 24	$150M	$135M	$16M
Q1 25	$125M	$114M	-$8M
Q2 25	$155M	$139M	-$9M
Q3 25	$169M	$148M	$34M
Q4 25	$185M	$157M	$16M

Valuation

Quarter	P/S	P/E
Q1 22	14.3x	—
Q2 22	14.2x	—
Q3 22	14.1x	—
Q4 22	13.8x	—
Q1 23	13.5x	—
Q2 23	13.0x	—
Q3 23	12.2x	—
Q4 23	11.4x	—
Q1 24	10.7x	—
Q2 24	10.0x	—
Q3 24	9.2x	—
Q4 24	8.6x	—
Q1 25	8.4x	—
Q2 25	8.0x	—
Q3 25	7.6x	—
Q4 25	7.2x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$58M	-$59M
Q2 22	-$16M	-$16M
Q3 22	-$12M	-$11M
Q4 22	-$81M	-$83M
Q1 23	-$18M	-$20M
Q2 23	-$16M	-$18M
Q3 23	-$38M	-$40M
Q4 23	$3M	$2M
Q1 24	-$30M	-$32M
Q2 24	$23M	$22M
Q3 24	-$23M	-$23M
Q4 24	-$4M	-$4M
Q1 25	$8M	$8M
Q2 25	-$27M	-$29M
Q3 25	$36M	$35M
Q4 25	$16M	$16M

Capital Expenditures

Quarter	CapEx
Q1 22	$871.0K
Q2 22	$355.0K
Q3 22	$137.0K
Q4 22	$3M
Q1 23	$2M
Q2 23	$2M
Q3 23	$2M
Q4 23	$2M
Q1 24	$2M
Q2 24	$1M
Q3 24	$356.0K
Q4 24	$288.0K
Q1 25	$212.0K
Q2 25	$2M
Q3 25	$382.0K
Q4 25	$299.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	+18.5%	+29.0%
Q2 22	+4.3%	+21.6%
Q3 22	+2.7%	-5.3%
Q4 22	+7.2%	-15.5%
Q1 23	+9.6%	-19.6%
Q2 23	+17.1%	-19.8%
Q3 23	+26.7%	+4.3%
Q4 23	+30.6%	-8.9%
Q1 24	+28.0%	+11.5%
Q2 24	+34.0%	-1.5%
Q3 24	+36.7%	-0.6%
Q4 24	+30.1%	+12.6%
Q1 25	+13.4%	-3.6%
Q2 25	+22.1%	+47.0%
Q3 25	+19.5%	+12.5%
Q4 25	+23.7%	+26.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$31M	38.9%
Q2 22	$12M	15.4%
Q3 22	$15M	18.1%
Q4 22	$19M	21.1%
Q1 23	$35M	40.4%
Q2 23	$17M	17.5%
Q3 23	$17M	16.0%
Q4 23	$0	0.0%
Q1 24	$31M	27.9%
Q2 24	$16M	12.8%
Q3 24	$19M	13.2%
Q4 24	$19M	12.8%
Q1 25	$25M	20.1%
Q2 25	$18M	11.4%
Q3 25	$18M	10.7%
Q4 25	$27M	14.4%

OpEx Breakdown

Quarter	R&D	SG&A
Q1 22	$82M	$58M
Q2 22	$78M	$53M
Q3 22	$53M	$47M
Q4 22	$64M	$54M
Q1 23	$41M	$74M
Q2 23	$35M	$65M
Q3 23	$41M	$66M
Q4 23	$35M	$70M
Q1 24	$28M	$88M
Q2 24	$25M	$74M
Q3 24	$26M	$75M
Q4 24	$30M	$87M
Q1 25	$28M	$92M
Q2 25	$61M	$85M
Q3 25	$23M	$90M
Q4 25	$24M	$117M

Revenue by Geography

Quarter	Non-US	United States
Q1 22	$55M	$24M
Q2 22	$53M	$28M
Q3 22	$51M	$30M
Q4 22	$54M	$34M
Q1 23	$57M	$29M
Q2 23	$57M	$37M
Q3 23	$66M	$38M
Q4 23	$72M	$43M
Q1 24	$73M	$37M
Q2 24	$77M	$50M
Q3 24	$85M	$56M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$233M	$178M	$411M
Q2 22	$236M	$151M	$387M
Q3 22	$278M	$77M	$355M
Q4 22	$149M	$145M	$294M
Q1 23	$161M	$107M	$267M
Q2 23	$211M	$54M	$266M
Q3 23	$263M	$17M	$280M
Q4 23	$247M	$39M	$286M
Q1 24	$210M	$30M	$240M
Q2 24	$209M	$51M	$260M
Q3 24	$234M	$16M	$250M
Q4 24	$214M	$36M	$250M
Q1 25	$182M	$69M	$251M
Q2 25	$159M	$72M	$231M
Q3 25	$191M	$73M	$264M
Q4 25	$214M	$80M	$294M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	288M	+3.4%	+9.1%
Q2 22	292M	+1.2%	+9.6%
Q3 22	289M	-0.9%	+8.1%
Q4 22	281M	-2.8%	+0.8%
Q1 23	291M	+3.6%	+1.0%
Q2 23	293M	+0.5%	+0.3%
Q3 23	296M	+1.0%	+2.3%
Q4 23	294M	-0.7%	+4.4%
Q1 24	303M	+3.2%	+4.0%
Q2 24	304M	+0.3%	+3.7%
Q3 24	305M	+0.3%	+3.0%
Q4 24	299M	-1.9%	+1.9%
Q1 25	308M	+2.9%	+1.6%
Q2 25	308M	+0.2%	+1.5%
Q3 25	310M	+0.7%	+1.9%
Q4 25	314M	+1.3%	+5.1%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$158.7K	496
Q2 22	$162.8K	496
Q3 22	$164.7K	496
Q4 22	$182.0K	484
Q1 23	$178.2K	484
Q2 23	$195.3K	484
Q3 23	$213.8K	484
Q4 23	$222.6K	517
Q1 24	$213.5K	517
Q2 24	$245.0K	517
Q3 24	$273.7K	517
Q4 24	$300.0K	499
Q1 25	$251.0K	499
Q2 25	$310.0K	499
Q3 25	$338.8K	499
Q4 25	$362.5K	511

Revenue / Employee